Company Overview
Dianthus Therapeutics
DNTH is a clinical-stage biotech developing next-generation monoclonal antibodies that modulate the complement system for severe autoimmune and neuromuscular diseases. Lead asset DNTH103 uses convenient subcutaneous dosing every two weeks, aiming to disrupt the gMG and CIDP markets projected to exceed $10B by 2030.
Key Catalysts
Phase 2 Momentum in gMG: The MaGic trial showed meaningful symptom improvement, supporting advancement toward Phase 3 and reinforcing a best-in-class profile.
CIDP Expansion: Planning a potentially registrational CIDP trial, extending the neuromuscular franchise and adding a second, sizable indication.
Platform Validation: Positive data backs DNTH’s precision immunology approach; q2w SC dosing directly addresses patients’ convenience and adherence needs.
Diversified Pipeline: Additional programs in rare inflammatory disorders create a multi-catalyst path through 2026, broadening the complement footprint.
Why It Matters
✅ High-value indications with unmet needs
✅ Differentiated dosing + mechanism
✅ Clear clinical path with near/medium-term readouts
Investment Outlook
Bullish above: $35.00–$36.00
Target: $80.00–$82.00 — driven by Phase 3 readiness in gMG, CIDP registrational potential, and complement-medicine leadership.
Dianthus Therapeutics
DNTH is a clinical-stage biotech developing next-generation monoclonal antibodies that modulate the complement system for severe autoimmune and neuromuscular diseases. Lead asset DNTH103 uses convenient subcutaneous dosing every two weeks, aiming to disrupt the gMG and CIDP markets projected to exceed $10B by 2030.Key Catalysts
Phase 2 Momentum in gMG: The MaGic trial showed meaningful symptom improvement, supporting advancement toward Phase 3 and reinforcing a best-in-class profile.
CIDP Expansion: Planning a potentially registrational CIDP trial, extending the neuromuscular franchise and adding a second, sizable indication.
Platform Validation: Positive data backs DNTH’s precision immunology approach; q2w SC dosing directly addresses patients’ convenience and adherence needs.
Diversified Pipeline: Additional programs in rare inflammatory disorders create a multi-catalyst path through 2026, broadening the complement footprint.
Why It Matters
✅ High-value indications with unmet needs
✅ Differentiated dosing + mechanism
✅ Clear clinical path with near/medium-term readouts
Investment Outlook
Bullish above: $35.00–$36.00
Target: $80.00–$82.00 — driven by Phase 3 readiness in gMG, CIDP registrational potential, and complement-medicine leadership.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.